Director, Mayo Clinic Cancer Center; William J. and Charles H. Mayo Professor, Professor, Pharmacology and Oncology, Mayo Medical School
Oncology
Dr. Robert B. Diasio, MD
|
|
Give Review
Robert Diasio practices Oncology. He researched medicine at Yale University School of Medicine. Yale University School of Medicine is a top medical college. Yale University School of Medicine is ranked 7 in research and 57 in primary care medicine He received awards:"Elected Member" and "Fellow". Dr. Robert B. Diasio is a published physician. He published 52 publications, including: 'Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance).'
Publications
- Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance).
- Association Study of the let-7 miRNA-Complementary Site Variant in the 3' Untranslated Region of the KRAS Gene in Stage III Colon Cancer (NCCTG N0147 Clinical Trial).
- Comparative Functional Analysis of DPYD Variants of Potential Clinical Relevance to Dihydropyrimidine Dehydrogenase Activity.
- MicroRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites.
- A DPYD Variant (Y186C) Specific to Individuals of African Descent in a Patient With Life-Threatening 5-FU Toxic Effects: Potential for an Individualized Medicine Appro...
- Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapy.
- Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.
- Response to "A Case of 5-FU-Related Severe Toxicity Associated With the P.Y186C DPYD Variant"
- HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma.
- Combined vitamin C and E deficiency induces motor defects in gulo(-/-)/SVCT2(+/-) mice.
- A DPYD variant (Y186C) in individuals of African ancestry associated with reduced DPD enzyme activity.
- Fatty acid binding protein 3 (fabp3) is associated with insulin, lipids and cardiovascular phenotypes of the metabolic syndrome through epigenetic modifications in a N...
- Phenotypic Profiling of DPYD Variations Relevant to 5-Fluorouracil Sensitivity Using Real-time Cellular Analysis and In Vitro Measurement of Enzyme Activity.
- New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: Cancer and leukemia group B 8461.
- Single-nucleotide polymorphism rs1052501 associated with monoclonal gammopathy of undetermined significance and multiple myeloma.
- The clinical case for proton beam therapy.
- Overall survival and self-reported fatigue in patients with esophageal cancer.
- A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC).
- A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11.
- Adverse Prognostic Impact of Intratumor Heterogeneous HER2 Gene Amplification in Patients With Esophageal Adenocarcinoma.
- EGFR somatic mutations in lung tumors: radon exposure and passive smoking in former- and never-smoking U.S. women.
- Identification of a novel percent mammographic density locus at 12q24.
- Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas.
- Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenocarcinoma.
- A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer.
- Common breast cancer susceptibility loci are associated with triple-negative breast cancer.
- Toxic encephalopathy in elderly patients during treatment with capecitabine: literature review and a case report.
- The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection.
- ADAM-17: a target to increase chemotherapeutic efficacy in colorectal cancer?
- Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism.
- Capecitabine-related cardiotoxicity: recognition and management.
- Palmar-plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dihydropyrimidine dehydrogenase: is there a pharmacolog...
- Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase.
- DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS.
- Genetic testing in cancer therapeutics.
- Methylation of the DPYD promoter and dihydropyrimidine dehydrogenase deficiency.
- Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abs...
- Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome.
- E1A-F is overexpressed early in human colorectal neoplasia and associated with cyclooxygenase-2 and matrix metalloproteinase-7.
- Edotecarin: a novel topoisomerase I inhibitor.
- Perspectives in the treatment of colorectal cancer.
- Adjuvant chemotherapy for adenocarcinoma of the lung--is the standard of care ready for change?
- Capecitabine induces rapid, sustained response in two patients with extensive oral verrucous carcinoma.
- Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using cap...
- A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase de...
- Can eniluracil improve 5-fluorouracil therapy?
- Housekeeping gene variability in normal and carcinomatous colorectal and liver tissues: applications in pharmacogenomic gene expression studies.
- Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
- Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype.
- An evolving role for oral fluoropyrimidine drugs.
- Quantitation of cytosine deaminase mRNA by real-time reverse transcription polymerase chain reaction: a sensitive method for assessing 5-fluorocytosine toxicity in vitro.
Schools
Yale University
Doctors Specialties
- Oncology
Accepted Insurances
Awards
- Elected Member
- Fellow
Education
-
University of Rochester -
Yale University School of Medicine
Hospital
-
Mayo Clinic - Rochester, Minnesota
Helpful Reviews
Similar Doctors
|
|
Dr. Charles L. Loprinzi, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Brian A. Costello, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas M. Pisansky, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Manish Kohli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ronald L. Richardson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Prema P. Peethambaram, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy J. Moynihan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Frank A. Sinicrope, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Axel F. Grothey, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Evanthia Galanis, MD
This Doctor is OpenDoctor Recommended.
|